- COVID-19 Lung Injury is Not High Altitude Pulmonary Edema
Authors correct the misconception that COVID- 19 lung injury is not like typical acute respiratory distress syndrome (ARDS) and instead is similar to high altitude pulmonary edema (HAPE). They argue that treatments for HAPE may exacerbate ARDS.
- Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19
Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.
- Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City
A cross-sectional analysis of 4,103 patients with laboratory-confirmed COVID-19 at a single academic health system in New York City. Age and comorbidities are powerful predictors of hospitalization; however, admission oxygen impairment and markers of inflammation are most strongly associated with critical illness.
- Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial
A 150 patient open-label randomized study comparing hydroxychloroquine to standard of care failed to demonstrate a difference in the primary endpoint of PCR viral clearance at day 28. Treatment was started a mean16.6 days after symptom onset. A secondary endpoint on “alleviating symptoms” was reported as significant however it was only in a minority of the total patients enrolled.